alanine has been researched along with Dyslipidemia in 9 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 9.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 5.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Obesity was negatively associated to clinical improvement after Remdesivir (OR 0." | 1.72 | The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study. ( Biondi, G; Brugaletta, G; Oliveri, R; Romano, M; Romano, R; San Lio, PM; Scicali, R; Tumminia, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, K | 1 |
| Suda, G | 1 |
| Yamamoto, Y | 1 |
| Abiko, S | 1 |
| Kinoshita, K | 1 |
| Miyamoto, S | 1 |
| Sugiura, R | 1 |
| Kimura, M | 1 |
| Maehara, O | 1 |
| Yamada, R | 1 |
| Kitagataya, T | 1 |
| Shigesawa, T | 1 |
| Ohara, M | 1 |
| Kawagishi, N | 1 |
| Nakai, M | 1 |
| Sho, T | 1 |
| Natsuizaka, M | 1 |
| Morikawa, K | 1 |
| Ogawa, K | 1 |
| Sakamoto, N | 1 |
| Lin, HY | 1 |
| Tseng, TC | 1 |
| Tumminia, A | 1 |
| Romano, R | 1 |
| Brugaletta, G | 1 |
| Scicali, R | 1 |
| Biondi, G | 1 |
| Oliveri, R | 1 |
| Romano, M | 1 |
| San Lio, PM | 1 |
| Hwang, EG | 1 |
| Jung, EA | 1 |
| Yoo, JJ | 1 |
| Kim, SG | 1 |
| Kim, YS | 1 |
| Kuo, PH | 1 |
| Sun, HY | 1 |
| Chuang, YC | 1 |
| Wu, PY | 1 |
| Liu, WC | 1 |
| Hung, CC | 1 |
| Li, YN | 1 |
| Su, Y | 1 |
| Gazzola, L | 1 |
| Tagliaferri, G | 1 |
| De Bona, A | 1 |
| Mondatore, D | 1 |
| Borsino, C | 1 |
| Bini, T | 1 |
| Marchetti, G | 1 |
| d'Arminio Monforte, A | 1 |
| Vilahur, G | 1 |
| Casani, L | 1 |
| Mendieta, G | 1 |
| Lamuela-Raventos, RM | 1 |
| Estruch, R | 1 |
| Badimon, L | 1 |
| Zhao, T | 1 |
| Nzekebaloudou, M | 1 |
| lv, J | 1 |
2 reviews available for alanine and Dyslipidemia
| Article | Year |
|---|---|
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H | 2023 |
Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis.
Topics: Adolescent; Adult; Alanine; Alleles; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fatty Acid-B | 2010 |
1 trial available for alanine and Dyslipidemia
| Article | Year |
|---|---|
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Dyslipidemias; Female; Hepatitis B virus; Hepatitis B, Chro | 2022 |
6 other studies available for alanine and Dyslipidemia
| Article | Year |
|---|---|
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Dyslipidemias; Humans; | 2022 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipi | 2020 |
Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Antiviral Agents; Diet, High-Fat; D | 2020 |
Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
Topics: Alanine; Dyslipidemias; HIV Infections; Humans; Tenofovir | 2021 |
Beer elicits vasculoprotective effects through Akt/eNOS activation.
Topics: Acetylcholine; Alanine; Animals; Beer; Cholesterol; Coronary Artery Disease; Coronary Vessels; Diet, | 2014 |